• 1
    Lee MW. Hepatitis B infection. N Engl J Med 1997; 337: 17331745.
  • 2
    Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. HEPATOLOGY 2001; 33: 15271532.
  • 3
    Marcellin P, Chang TT, Lim SG, Tong M, Sievert W, Shiffman M, et al. GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results. HEPATOLOGY 2001; 34: 340A.
  • 4
    Chu CK, Ma T, Shanmuganathan K, Wang C, Xiang Y, Pai SB, et al. Use of 2′-fluoro-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995; 39: 979981.
  • 5
    Yao GQ, Liu SH, Chou E, Kukhanova M, Chu CK, Cheng YC. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2′-fluoro-β-L-arabinofuranosyluracil. Biochem Pharmacol 1996; 51: 941947.
  • 6
    Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β–D-2,6-diaminopurine and 2′-fluoro-β-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45: 24952501.
  • 7
    Pai SB, Liu SH, Zhu YL, Chu CK, Cheng YC. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-β-L-arabinofuranosyluracil. Antimicrob Agents Chemother 1996; 40: 380386.
  • 8
    Ma T, Pai SB, Zhu YL, Lin JS, Shanmuganathan K, Du J, et al. Structure-activity relationships of 1-(2-deoxy-2-fluoro-β-L-arabinofuranosyluracil) pyrimidine nucleosides as anti-hepatitis B virus agents. J Med Chem 1996; 39: 28352843.
  • 9
    Liu SH, Grove KL, Cheng YC. Unique metabolism of a novel antiviral L-nucleoside analog, 2′-fluoro-β-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deosycytidine kinase. Antimicrob Agents Chemother 1998; 42: 833839.
  • 10
    Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, et al. Antiviral activity of clevudine [L-FMAU, (1- (2-fluoro-5–methyl β-L-arabinofuranosyl)uracil)] against woodchuck hepatitis virus and gene expression in chronically infected woodchucks (Marmota monax). HEPATOLOGY 2001; 33: 254266.
  • 11
    Chu CK, Boudinot FD, Peek SF, Hong JH, Choi Y, Korba BE, et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther 1998; 3( suppl 3): 113121.
  • 12
    Blum MR, Chittick G, Wang L, Fang L, Szczech G, Rousseau F. Phase I pharmacokinetic and safety evaluation of clevudine (L-FMAU), a new agent under development for the treatment of hepatitis B virus (HBV) infection. Presented at: Interscience Conference on antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto, Ontario, Canada.
  • 13
    Lau GKK, Tsiang M, Hou J, Carman WF, Zhang L, Gibbs CS, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. HEPATOLOGY 2000; 32: 394399.
  • 14
    De Man R, Wolters LMM, Nevens F, Chua D, Sherman M, Lai CL, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. HEPATOLOGY 2001; 34: 578582.
  • 15
    Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepatol 1999; 6: 387395.
  • 16
    Mels GC, Bellati G, Leandro G, Brunetto MR, Vicari O, Borzio M, et al. Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. Liver 1994; 14: 175181.
  • 17
    Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich C, Miller DS, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75: 311322.